Chronic Urticaria Or Hives - Pipeline Review, H2 2013, New Report Launched

Chronic Urticaria Or Hives - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chronic Urticaria Or Hives, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Urticaria Or Hives. Chronic Urticaria Or Hives - Pipeline Review, Half Year is built using data and information sourced from report proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team.

Scope

• A snapshot of the global therapeutic scenario for Chronic Urticaria Or Hives.
• A review of the Chronic Urticaria Or Hives products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Chronic Urticaria Or Hives pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Chronic Urticaria Or Hives.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 76 pages, 27 Tables and 16 Figures “Chronic Urticaria Or Hives - Pipeline Review, H2 2013” report provide Chronic Urticaria Or Hives Overview, Therapeutics Development, Chronic Urticaria Or Hives - Therapeutics under Development by Companies, Chronic Urticaria Or Hives - Therapeutics under Investigation by Universities/Institutes, Chronic Urticaria Or Hives - Pipeline Products Glance,Clinical Stage Products, Drug Profiles, Product Description, Appendix and report cover 9 companies - Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., Merck & Co., Inc., Biofrontera AG, Sun Pharmaceutical Industries Limited, FAES Farma SA, AEterna Zentaris Inc., JDP Therapeutics Inc.

Inquiry for more information visit: http://www.marketresearchreports.com/global-markets-direct/chronic-urticaria-or-hives-pipeline-review-h2-2013

Find All Pharma and Healthcare Reports at: 

http://www.marketresearchreports.com/pharma-healthcare